Emmes is excited to share the significant progress being made in clinical studies we undertake for clients and to give you a look inside some of our own news.
Emmes Studies Contribute to FDA Approval of a Medical Device That Estimates the Weight of Infants
Emmes today announced that the U.S. Food and Drug Administration (FDA) has approved a prescription-only medical device used to estimate the weight of infants who are up to 90 days of age.
Emmes Will Support Development of a New Universal Flu Vaccine for The National Institute of Allergy and Infectious Diseases
Emmes today announced that it is part of a team of medical centers, universities and private industry supporting the development of a “universal influenza vaccine” that could provide longer-lasting protection than current vaccines and combat a wider variety of influenza viruses.
Emmes Names Lynn Lewis Chief Business Officer
Emmes today announced that Lynn Lewis has joined the company as chief business officer, a newly created position. Her overall focus is to build deeper relationships with existing clients and to develop new business opportunities, particularly among biotech and pharmaceutical companies.
Emmes Awarded New NIH Contracts that Address the Nation’s Opioid Addiction Crisis
Emmes today announced the award of eight new task order contract awards associated with the Helping to End Addiction Long-term℠ Initiative, known as the NIH HEAL Initiative℠. The total value for the eight contracts is more than $9 million. The contract awards’ duration ranges from one to five years.
Emmes Ranked as a Top Private Company
Emmes today announced that it was ranked as one of the 100 largest private companies in the Washington metropolitan area. The ranking is compiled annually by the Washington Business Journal. The company was ranked as the 83rd largest private company this year. Its most recently reported revenues were more than $114 million, and about 600 of the company’s 725 employees work in the Washington area.
Emmes Honored for Workplace Excellence
Emmes today announced that it has received a Workplace Excellence Seal of Approval from Alliance for Workplace Excellence (AWE). This is the fifth consecutive year the company has received the AWE Workplace Excellence award.
Regulatory update: PRRC
New Medical Device Guidance on Article 15 of the MDR and IVDR regarding person responsible for regulatory compliance
Emmes-Supported Study Results in the First Pediatric Drug Labeling Change for 2019
Emmes today announced that it provided the data management support for a study, funded by the National Institutes of Health (NIH) and approved by the Food and Drug Administration (FDA), to safely use Acyclovir to treat infants infected with the Herpes Simplex Virus. Acyclovir, known by the brand name Zovirax, now includes recommended usage and dosage for newborns and infants up to three months of age on its label.
Neox's work recognized in Athero Review
Congrats to the Neox team and their work, which was recognized in a recent publication
Behrman Capital Makes Significant Investment in Emmes
Emmes today announced that Behrman Capital, a leading private equity firm, has made a significant investment in the company. The capital will allow Emmes, one of the Washington area’s top 100 largest private companies, to expand and strengthen its service offerings and international presence.
The Washington Business Journal Recognizes Emmes in Two "Top Company" Lists
The Emmes Corporation today announced that it was named one of the largest women-owned businesses in the Washington metropolitan area by the Washington Business Journal. Emmes was ranked the sixth largest women-owned business in the Washington region, up from number seven last year. Last month, Emmes was named as one of the top 100 largest private companies in the area. Emmes ranked 83rd, up from 95th the previous year, in the Washington Business Journal’s annual list.
PRINCIPLES OF PERSONAL DATA PROCESSING & PROTECTION
This is to inform you about how your personal data is processed by NEOX s.r.o. These principles describe how your personal data is obtained and processed. At the same time, please be assured that any and all personal data processed is considered as strictly confidential by NEOX s.r.o. and is handled in compliance with applicable legal regulations. Personal data is under the control and protection of NEOX s.r.o., and NEOX s.r.o. has established mechanisms to ensure an adequate protection of processed personal data against its misuse.